Acacemic Excellence Award (February 2024)

Novel therapeutic strategy for anaplastic thyroid cancer 

January 10, 2024 Announced by Joong Ang

January 10, 2024 Announced by Chosun

January 10, 2024 Announced by Hankook

January 10, 2024 Announced by Kyunghyang

Co-inhibition of glutaminolysis and one carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer

Hwang Y et al., Cell Death and Disease 2024

Novel therapeutic targets for refractory gastric cancer 

June 15, 2023 Announced by The Korean Economic Daily

June 15, 2023 Announced by Seoul Shinmun

Jun 15, 2023 Announced by Edaily news

PHGDH preserves one-carbon cycle to confer metabolic plasticity in chemoresistant gastric cancer during nutrient stress

Yoon BK & Kim H et al., PNAS 2023

Is ROR alpha a promising IBD therapeutic target? 

October 17, 2019 Announced by The Financial News

October 17, 2019 Announced by Yonhap News Agency

October 17, 2019 Announced by Newsis

Intestinal ROR alpha negatively controls NFkB transcriptional network in response to exogenous inflammatory signaling to protect against inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. 

Oh SK et al., PNAS 2019

ROR alpha protects against NAFLD pathogenesis

August 27, 2017 Announced by Seoul Economic Daily

August 27, 2017 Announced by No Cut News

August 27, 2017 Announced by The Asia Business Daily

Hepatic ROR alpha negatively controls PPAR gamma transcriptional network to protect against diet-induced obesity and Non-Alcoholic Fatty Liver Disease (NAFLD).

Kim K et al., Nature Communications 2017